The statins as anticancer agents

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 10-19

  Chan, Kelvin K W ^a   Oza, Amit M ^a   Siu, Lillian L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CYCLOSPORIN A; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; NICOTINIC ACID; STATINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CARDIOVASCULAR DISEASE; CELL CYCLE; CELL FUNCTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; LIVER TOXICITY; METASTASIS; MUSCLE DISEASE; MYALGIA; MYOGLOBINURIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RHABDOMYOLYSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MODELS, BIOLOGICAL; NEOPLASM METASTASIS;

EID: 0037233011     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (98)

1. Goldstein, J. L., and Brown, M. S. Regulation of the mevalonate pathway. Nature (Lond.), 343: 425-430, 1990.
2. Endo, A., and Kuroda, M. Citrinin. an inhibitor of cholesterol synthesis. J. Antibiot. (Tokyo), 29: 841-843, 1976.
3. Ness, G. C., Zhao, Z., and Lopez, D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch. Biochem. Biophys., 325: 242-248, 1996.
4. Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., MacFarlane, P. W., McKillop, J. H., and Packard, C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med., 333: 1301-1307, 1995.
5. Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., and Gotto, A. M., Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J. Am. Med. Assoc., 279: 1615-1622, 1998.
6. Scandinavian Simvastatin Survival Study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344: 1383-1389, 1994.
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 339: 1349-1357, 1998.
8. Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M., Wun, C. C., Davis, B. R., and Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med., 335: 1001-1009, 1996.
9. Hebert, P. R., Gaziano, J. M., Chan, K. S., and Hennekens, C. H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. J. Am. Med. Assoc., 278: 313-321, 1997.
10. Bucher, H. C., Griffith, L. E., and Guyatt, G. H. Effect of HMG-CoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann. Intern. Med., 128: 89-95, 1998.
11. Crouse, J. R., III, Byington, R. P., Hoen, H. M., and Furberg, C. D. Reductase inhibitor monotherapy and stroke prevention. Arch. Intern. Med., 157: 1305-2310, 1997.
12. Byington, R. P., Davis, B. R., Plehn, J. F., White, H. D., Baker, J., Cobbe, S. M., and Shepherd, J. Reduction of Stroke Events with Pravastatin: the prospective Pravastatin Pooling (PPP) Project. Circulation, 103: 387-392, 2001.
13. Farmer, J. A. Pleiotropic effects of statins. Curr. Atherosclero. Rep., 2: 208-217, 2000.
14. Gotto, A. M., Jr., and Farmer, J. A. Pleiotropic effects of statins: do they matter? Curr. Opin. Lipidol., 12: 391-394, 2001.
15. LaRosa, J. C. Pleiotropic effects of statins and their clinical significance. Am. J. Cardiol., 88: 291-293, 2001.
16. Schwartz, G. G., Olsson, A. G., Ezekowitz, M. D., Ganz, P., Oliver, M. F., Waters, D., Zeiher, A., Chaitman, B. R., Leslie, S., and Stern, T. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. J. Am. Med. Assoc., 285: 1711-1718, 2001.
17. Alberts, M. J. Suppression of recurrent transient ischemic attacks by a statin agent. Neurology, 56: 531-532, 2001.
18. Bellosta, S., Ferri, N., Bernini, F., Paoletti, R., and Corsini, A. Non-lipid-related effects of statins. Ann. Med., 32: 164-176, 2000.
19. Edwards, P. A., and Ericsson, J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu. Rev. Biochem., 68: 157-185, 1999.
20. Stocker, R., Bowry, V. W., and Frei, B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does α-tocopherol. Proc. Natl. Acad. Sci. USA, 88: 1646-1650, 1991.
21. Jackson, S. M., Ericsson, J., and Edwards, P. A. Signalling molecules derived from the cholesterol biosynthetic pathway. Subcell. Biochem., 28: 1-21, 1997.
22. Germershausen, J. I., Hunt, V. M., Bostedor, R. G., Bailey, P. J., Karkas, J. D., and Alberts, A. W. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin, and pravastatin in rats in vivo. Biochem. Biophys. Res. Commun., 158: 667-675, 1989.
23. American Medical Association. Drug Evaluations, p. 2486. 1995.
24. Mohammed, H. M. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme coenzynic A reductase inhibitors, Vol III. Chicago: Life Sci., 65: 1329-1337, 1999.
25. Maron, D. J., Fazio, S., and Linton, M. F. Current perspectives on statins. Circulation, 101: 207-213, 2000.
26. Farmer, J. A., and Torre-Amione. G. Comparative tolerability of the HMG-CoA reductase Inhibitors. Drug Saf., 23: 197-213, 2000.
27. Tobert, J. A. Efficacy and long term adverse effect pattern of lovastatin. Am J. Cardiol., 62: 28-34, 1988.
28. Baker, S. K., and Tarnopolsky, M. A. Statin myopathies: pathophysiologic and clinical perspective. Clin. Investig. Med., 24: 258-272, 2001.
29. Chariot, P., Abadia, R., Agnus, D., Danan, C., Charpentier, C., and Gherardi, R. K. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am. J. Med., 94: 109-110, 1993.
30. Walravens, P. A., Greene, C., and Frerman, F. E. Lovastatin, isoprenes, and myopathy. Lancet, 2: 1097-1098, 1989.
31. Laaksonen, R., Joklainen, K., Laakso, J., Sahi, T., Harkonen, M., Tikkanen, M. J., and Himberg, J. J. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphate and ubiquinone in skeletal muscle. Am. J. Cardiol., 77: 851-854, 1996.
32. Laaksonen, R., Jokelainen, K., Sahi, T., Tikkanen, M. J., and Himberg, J. J. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin. Pharmacol. Ther., 57: 62-66, 1995.
33. Pierno, S., De Luca, A., Tricarico, D., Roselli, A., Natuzzi, F., Ferrannini, E., Laico, M., and Camerino, D. C. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibres. J. Pharmacol. Exp. Ther., 275: 1490-1496, 1995.
34. Gray, D. F., Bundgaard, H., Hansen, P. S., Buhagiar, K. A., Mihailidou, A. S., Jessup, W., Kjeldsen, K., and Rasmussen, H. H. HMG-CoA reductase inhibition reduces sarcolemmal Na(+)-K(+) pump density. Cardiovasc. Res., 47: 329-335, 2000.
35. Pierno, S., De Luca, A., Liantonio, A., Camerino, C., and Conte Camerino, D. Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle. Eur. J. Pharmacol., 364: 43-48, 1999.
36. Mutoh, T., Kumano, T., Nakagawa, H., and Kuriyama, M. Role of tyrosine phosphorylation of phospholipase C γ 1 in the signaling pathway of HMG-CoA reductase-induced cell death of L6 myoblast. FEBS Lett., 446: 91-94, 1999.
37. Smith, P. F., Eydelloth, R. S., Grossman, S. J., Stubbs, R. J., Schwartz, M. S., Germershausen, J. I., Vyas, K. P., and Kari, P. H. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporin A interaction and mechanism studies. J. Pharmacol. Exp. Ther., 257: 1225-1235, 1991.
38. Pierce, L. R., Wysowski, D. K., and Gross, T. P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. J. Am. Med. Assoc., 264: 71-75, 1990.
39. Masters, B. A., Palmoski, M. J., Flint, O. P., Gregg, R. E., Wang-Iverson, D., and Durham, S. K. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzymeA reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol. Appl. Pharmacol., 131: 163-174, 1995.
40. Ucar, M., Mjorndal, T., and Dahlqvist, R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf., 22: 441-457, 2000.
41. Jacobs, D., Blackburn, H., Higgins, M., Reed, D., Iso, H., McMillan, G., Neaton, J., Nelson, J., Potter, J., and Rifkind, B. Report of the conference on low blood cholesterol: mortality associations. Circulation, 86: 1046-1060, 1992.
42. Newman, T. B., and Hulley, S. B. Carcinogenicity of lipid-lowering drugs. J. Am. Med. Assoc., 275: 55-60, 1996.
43. Kritchevsky, S. B. Dietary lipids and the low blood cholesterol-cancer association. Am. J. Epidemiol., 135: 509-520, 1992.
44. Eichholzer, M., Stahelin, H. B., Gutzwiller, F., Ludin, E., and Bernasconi, F. Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am. J. Clin. Nutr., 71: 569-574, 2000.
45. Law, M. R., and Thompson, S. G. Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer Causes Control, 2: 253-261, 1991.
46. Law, M. R., Thompson, S. G., and Wald, N. J. Assessing possible hazards of reducing serum cholesterol. BMJ, 308: 373-379, 1994.
47. Pedersen, T. R., Wilhelmsen, L., Faergeman, O., Strandberg, T. E., Thorgeirsson, G., Troedsson, L., Kristianson, J., Berg, K., Cook, T. J., Haghfelt, T., Kjekshus, J., Miettinen, T., Olsson, A. G., Pyorala, K., and Wedel, H. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am. J. Cardiol., 86: 257-262, 2000.
48. Bjerre, L. M., and Lelorier, J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am. J. Med., 110: 716-723, 2001.
49. Blais, L., Desgagne, A., and LeLorier, J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer. A nested case-control study. Arch. Intern. Med., 160: 2363-2368, 2000.
50. 1 to multiple cell cycles by Lovastatin. Cancer Res., 51: 3602-3609, 1991.
51. Bouterfa, H. L., Sattelmeyer, V., Czub, S., Vordermark, D., Roosen, K., and Tonn, J. C. Inhibition of Ras farnesylation by lovastatin leads to down-regulation of proliferation and migrating in primary cultured human gliblastoma cells. Anticancer Res., 20: 2761-2771, 2000.
52. DeClue, J. E., Vass, W. C., Papageorge, A. G., Lowy, E. R., and Willumsen, B. M. Inhibition of cell growth by Lovastatin is independent of ras funtion. Cancer Res., 51: 712-717, 1991.
53. Crick, D. C., Andres, D. A., Danesi, R., Macchia, M., and Waechter, C. J. Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J. Neurochem., 70: 2397-2405, 1998.
54. Clutterbuck, R. D., Millar, B. C., Powles, R. L., Newman, A., Catovsky, D., Jarman, M., and Millar, J. L. Inhibitory effect of simvastatin on the proliferation of human myeloid leukemia cells in severe combined immunodeficient (SCID) mice. Br. J. Haematol., 102: 522-527, 1998.
55. Ghosh, P. M., Ghosh-Choudhury, N., Moyer, M. L., Mott, G. E., Thomas, C. A., Foster, B. A., Greenberg, N. M., and Kreisberg, J. I. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene, 18: 4120-4130, 1999.
56. Denoyelle, C., Vasse, M., Korner, M., Mishal, Z., Ganne, F., Vannier, J. P., Soria, J., and Soria, C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis (Lond.), 22: 1139-1148, 2001.
57. Wachtershauser, A., Akoglu, B., and Stein, J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis (Lond.), 22: 1061-1067, 2001.
58. Lee, S. J., Ha, M. J., Lee, J., Nguyen, P., Choi, Y. H., Pirnia, F., Kang, W. K., Wang, X. F., Kim, S. J., and Trepel, J. B. Inhibition of the 3-hydroxy-3 methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells. J. Biol. Chem., 273: 10618-10623, 199.
59. 1-S phase in growth-stimulated rat FRTL-5 cells. J. Biol. Chem., 272: 13-16, 1997.
60. Xia, Z., Tan, M. M., Wong, W. W., Dimitroulakos, J., Minden, M. D., and Penn, L. Z. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia (Baltimore), 15: 1398-1407, 2001.
61. Agarwal, B., Bhendwal, S., Halmos, B., Moss, S. F., Ramey, W. G., and Holt, P. R. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin. Cancer Res., 5: 2223-2229, 1999.
62. Kusama, T., Mukai, M., Iwasaki, T., Tatsuta, M., Matsumoto, Y., Akedo, H., and Nakamura, H. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res., 61: 4885-4891, 2001.
63. Pazzaglia, S., Saran, A., Pariset, L., Rebessi, S., Di Majo, V., Coppola, M., and Covelli, V. Sensitivity of C3H 10T 1/2 cells to radiation induced killing and neoplastic transformation as a function of cell cycle. Int. J. Radiat. Oncol. Biol. Phys., 69: 57-65, 1996.
64. Langley, R. E., Quartuccio, S. G., Kennealey, P. T., Coleman, C. N., and Bump, E. A. Effect of cell cycle stage, dose rate and repair of sublethal damage on radiation-induced apoptosis in F9 teratocarcinoma cells. Radiat. Res., 144: 90-96, 1995.
65. McKenna, W. G., Weiss, M. C., Bakanauskas, V. J., Sandler, H., Kelsten, M. L., Biaglow, J., Tuttle, S. W., Endlich, B., Ling, C. C., and Muschel, R. J. The role of the H-Ras oncogene in radiation resistance and metastasis. Int. J. Radiat. Oncol. Biol. Phys., 18: 849-859, 1990.
66. Miller, A. C., Kariko, K., Myers, C. E., Clark, E. P., and Samid, D. Increased radioresistance of Ejras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int. J. Cancer. 53: 302-307, 1993.
67. Kornbrust, D. J., MacDonald, J. S., Peter, C. P., Duchai, D. M., Stubbs, R. J., Germershausen, J. I., and Alberts, A. W. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J. Pharmacol. Exp. Ther., 248: 498-505, 1989.
68. Pan, H. Y., DeVault, A. R., Wang-Iverson, D., Ivashkiv, E., Swanson, B. N., and Sugerman, A. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J. Clin. Pharmacol., 30: 1128-1135, 1990.
69. Prasanna, P., Thibault, A., Liu, L., and Samid, D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J. Neurochem., 66: 710-716, 1996.
70. Jones, K. D., Couldwell, W. T., Hinton, D. R., Su, Y., He, S., Anker, L., and Law, R. E. Lovastatin induces growth inhibition and apoptosis in human glioma cells. Biochem. Biophys. Res. Commun., 205: 1681-1687, 1994.
71. Marcelli, M., Cunningham, G. R., Haidacher, S. J., Padayatty, S. J., Sturgis, L., Kagan, C., and Denner, L. Caspase-7 is activated during lovastating-induced apoptosis of the prostate cancer cell line LNCAP. Cancer Res., 58: 76-83, 1998.
72. Dimitroulakos, J., and Yeger, H. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat. Med., 2: 326-333, 1996.
73. Dimitroulakos, J., Nohynek, D., Backway, K. L., Hedley, D. W., Yeger, H., Freedman, M. H., Minden, M. D., and Penn, L. Z. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood, 93: 1308-1318, 1999.
74. Dimitroulakos, J., Ye, L. Y., Benzaquen, M., Moore, M. J., Kamel-Reid, S., Freedman, M. H., Yeger, H., and Penn, L. Z. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin induced apoptosis: therapeutic implications. Clin. Cancer Res., 7: 158-167, 2001.
75. Macaulay, R. J., Wang, W., Dimitroulakos, J., Becker, L. E., and Yeger, H. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. J. Neurooncol., 42: 1-11, 1999.
76. Rubins, J. B., Greatens, T., Kratzke, R. A., Tan, A. T., Polunovsky, V. A., and Bitterman, P. Lovastatin induces apoptosis in malignant mesothelioma cells. Am. J. Respir. Crit. Care Med., 157: 1616-1622, 1998.
77. Soma, M. R., Pagliarini, P., Butti, G., Paoletti, R., Paoletti, P., and Fumagalli, R. Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N′bis(2-chloroethyl)-N-nitrosurea and β-interferon on human glioma cells. Cancer Res., 52: 4348-4355, 1992.
78. Feleszko, W., Zagozdzon, R., Golab, J., and Jakobisiak, M. Potentiated antitumor effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur. J. Cancer, 34: 406-411, 1998.
79. Feleszko, W., Mlynarczuk, I., Balkowiec-Iskra, E. Z., Czajka, A., Switaj, T., Stoklosa, T., Giermasz, A., and Jakobisiak, M. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin. Cancer Res., 6: 2044-2052, 2000.
80. Holstein, S., and Hohl, R. Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk. Res., 25: 651-660, 2001.
81. Lishner, M., Bar-Sef, A., Elis, A., and Fabian, I. Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J. Investig. Med., 49: 319-324, 2001.
82. Wong, W. W., Tan, M. M., Xia, Z., Dimitroulakos, J., Minden, M. D., and Penn, L. Z. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin. Cancer Res., 7: 2067-2075, 2001.
83. Inano, H., Suzuki, K., Onoda, M., and Wakabayashi, K. Anticarcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of rats. Carcinogenesis (Lond.), 18: 1723-1727, 1997.
84. Narisawa, T., Fukarua, Y., Tanida, N., Hasebe, M., Ito, M., and Aizawa, R. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in 1CR mice. Tohoku J. Exp. Med., 180: 131-138, 1996.
85. Narisawa, T., Morotomi, M., Fukaura, Y., Hasebe, M., Ito, M., and Aizawa, R. Chemoprevention by pravastatin, a 3-hydroxy-3methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn. J. Cancer Res., 87: 798-804, 1996.
86. Kikuchi, T., Nagata, Y., and Abe, T. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells. J. Neurooncol., 34: 233-239, 1997.
87. Hawk, M. A., Cesen, K. T., Siglin, J. C., Stoner, G. D., and Ruch, R. J. Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett., 109: 217-222, 1996.
88. Matar, P., Rozados, V. R., Binda, M. M., Roggero, E. A., Bonfil, R. D., and Scharovsky, O. G. Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Clin. Exp. Metastasis, 17: 19-25, 1999.
89. Matar, P., Rozados, V. R., Roggero, E. A., and Scharovsky, O. G. Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma. Cancer Biother. Radiopharm., 13: 387-393, 1998.
90. Alonso, D. F., Farina, H. G., Skilton, G., Gabri, M. R., De Lorenzo, M. S., and Gomez, D. E. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res. Treat., 50: 83-93, 1998.
91. Broitman, S. A., Wilkinson, J., IV, Cerda, S., and Branch, S. K. Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic "metastases" in vivo. Adv. Exp. Med. Biol., 401: 111-130, 1996.
92. Jani, J. P., Specht, S., Stemmler, M., Blanock, K., Singh, S. V., Gupta, V., and Katoh, A. Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis, 13: 314-324, 1993.
93. Feleszko, W., Balkowiec, E. Z., Sieberth, E., Marczak, M., Dabrowska, A., Giermasz, A., Czajka, A., and Jakobisiak, M. Lovastatin and tumor necrosis factor α exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int. J. Cancer, 81: 560-567, 1999.
94. Thibault, A., Samid, D., Tompkins, A. C., Figg, W. D., Cooper, M. R., Hohl, R. J., Trepel, J., Liang, B., Patronas, N., Venzon, D. J., Reed, E., and Myers, C. E. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res., 2: 483-491, 1996.
95. Larner, J., Jane, J., Laws, E., Packer, R., Myers, C., and Shaffrey, M. A Phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am. J. Clin. Oncol., 21: 579-583, 1998.
96. Kim, W. S., Kim, M. M., Choi, H. J., Yoon, S. S., Lee, M. H., Park, K., Park, C. H., and Kang, W. K. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Investig. New Drugs, 19: 81-83, 2001.
97. Kawata, S., Yamasaki, E., Nagase, T., Inui, Y., Ito, N., Matsuda, Y., Inada, M., Tamura, S., Noda, S., Imai, Y., Matsuzawa, Y. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer, 84(7): 886-891, 2001.
98. Knox, J. J., Siu, L. L., Kamel-Reid, S., Dimitroulakos, J., Moore, M. J., Lumb, K., Irish, J., LaFramboise, S., Gullane, P., McRae, S., Chin, S., and Oza, A. M. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) and of the cervix. Proceedings of the 2001 AACR-NCI-EORTC International Conference. Miami Beach, Florida, p. 71, 2001.